Christopher Vaughn, MD
Hematology & Oncology · Fredericksburg, VANPI 1851322499
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,658 of the $14,428 with a category attached, or 66.9%. 52 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 50.1% of the total. 2025 is the largest year on record at $6,826, 5.5 times the $1,250 reported in 2019. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $49.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- AstraZeneca$3K
- Pfizer$628
- Johnson & Johnson$575
- GSK$504
- Novartis$432
- plus $2K from 46 others
Across 225 payments — averaging $8528.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$644K
- E.r. Squibb & Sons, L.L.C.$491K
- Genentech, Inc.$202K
- Eli Lilly$193K
- GSK$172K
- Bristol Myers Squibb$153K
- plus $63K from 4 others
What the payments were for
- Consulting fees$9,65867%
- Food & beverage$4,62032%
- Education$1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$2,750
How this compares
$14,428 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 23 | $325,104 |
| XalkoriCrizotinib | 12 | $274,508 |
| ImbruvicaIbrutinib | 14 | $248,409 |
| JakafiRuxolitinib Phosphate | 13 | $226,755 |
| CalquenceAcalabrutinib Maleate | 15 | $225,100 |
| IbrancePalbociclib | 13 | $202,413 |
| Abiraterone Acetate | 18 | $53,800 |
| XareltoRivaroxaban | 54 | $50,223 |
| EliquisApixaban | 56 | $47,270 |
| OxycontinOxycodone Hcl | 13 | $34,215 |
| Imatinib Mesylate | 12 | $20,107 |
| Exemestane | 34 | $8,666 |
| Ondansetron Hcl | 30 | $5,768 |
| Enoxaparin Sodium | 14 | $2,470 |
| Anastrozole | 68 | $1,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXalkori, Ibrance, Eliquis | $628 | $524,19281 claims |
| Beigene USA, Inc.Brukinsa | $59 | $325,10423 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $102 | $248,40914 claims |
| Incyte CorporationJakafi | $25 | $226,75513 claims |
| AstraZenecaCalquence | $2,909 | $225,10015 claims |
| Johnson & JohnsonXarelto | $575 | $50,22354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Fredericksburg
- Sudeep MenacheryFredericksburg$34K
- Lakshminarayanan NandagopalFredericksburg$16K
- Charles MaurerFredericksburg$12K
- Lisa SimmonsFredericksburg$11K
- Keri BradshawFredericksburg$9K
- Bonny MooreFredericksburg$7K
- Majd IssaFredericksburg$6K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.